Featured Investment Ideas
- Synergy is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide
By Jake King · Tue, May 21
It doesn’t get much better than this, and Synergy Pharmaceuticals (SGYP) remains a favorite PropThink idea. The company’s lead drug candidate, plecanatide, has demonstrated strong safety and efficacy results in a 951-patient clinical trial, there’s a path to FDA approval, and the company is · more »
- PropThink’s Weekly Biotech Round-Up
By Editorial Staff · Fri, May 17 - Value Investors Take Note: Fire Sale on this Heart Failure Asset
By Jake King · Fri, May 17 - Trius Patent Intrigues Investors, And Perhaps Cubist Pharmaceuticals
By Jason Napodano, CFA · Thu, May 16
Latest News
- Cubist Commands the Courtroom: Investors Can Now Focus On Long-Term Story
By Jake King · Tue, May 21 - Revisiting Synergy Ahead of An Event-Driven Week: Plecanatide Data is Forthcoming
By Jake King · Fri, May 17 - An FDA Meeting Becomes New Focus for Titan Pharma
By Jason Napodano, CFA · Fri, May 17 - Ahead of Incremental Catalysts, Immunomedics’ Options are Compellingly Priced
By Ivan Deryugin · Wed, May 15
- MAKO Surgical: Burden of Proof Still on Management
By Jake King · Thu, May 9 - Previewing MAKO Surgical’s First Quarter: A Pivotal Earnings Release
By Ivan Deryugin · Mon, May 6 - The ODAC Postmortem: Lessons Learned Part 2, Delcath Systems
By Aafia Chaudhry, MD · Mon, May 6 - Picking Up What’s Left of Aveo
By Jake King · Fri, May 3
Most Popular
- Synergy is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide
By Jake King · Tue, May 21 - Cubist Commands the Courtroom: Investors Can Now Focus On Long-Term Story
By Jake King · Tue, May 21 - PropThink’s Weekly Biotech Round-Up
By Editorial Staff · Fri, May 17 - Revisiting Synergy Ahead of An Event-Driven Week: Plecanatide Data is Forthcoming
By Jake King · Fri, May 17
- An FDA Meeting Becomes New Focus for Titan Pharma
By Jason Napodano, CFA · Fri, May 17 - Value Investors Take Note: Fire Sale on this Heart Failure Asset
By Jake King · Fri, May 17 - Trius Patent Intrigues Investors, And Perhaps Cubist Pharmaceuticals
By Jason Napodano, CFA · Thu, May 16 - Ahead of Incremental Catalysts, Immunomedics’ Options are Compellingly Priced
By Ivan Deryugin · Wed, May 15
